| Revenue growth | Q2 +52% YoY; H1 +45% YoY |
|---|---|
| Margins | Q2 EBITDA 28% vs 20%; gross margin 48% vs 47% |
| Demand visibility | 69 oncology contracts executed; 45 commercial discussions underway |
Growth
Q2 revenue +52%, H1 +45%. EBITDA margin 28% vs 20%; PAT margin 13% vs 8%. H1 PAT +134%.
Outlook
No quantified guidance. Two-year targets: 100+ overseas contracts, 300+ dossier approvals, 20+ domestic partners.
Risks
H1 working-capital outflow Rs21.8 Cr; operating cash flow fell to Rs23.5 Cr from Rs30.6 Cr.
Last quarter's promises, checked
Delivered
- Guided 65+ oncology contracts → 69 (= BEAT)
- Affirmed Rs85-90 Cr quarterly run-rate → Q2 Rs87.4 Cr (= BEAT)
Partly delivered
- Guided 16 MAs doubling to ~32 in FY27 → 22 at H1 (= PARTIAL)
- Guided ~30% oncology EBITDA margin by FY-end → Q2 consolidated 28%, Q1 29% (= PARTIAL)
- Guided no major capex → H1 investing outflow Rs22.0 Cr (= PARTIAL)
Missed
- Guided 50+ advanced discussions → 45 (= MISS)
Investor Presentation filed with NSE, NSE: SAKAR. Summary written with AI assistance from the document.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹996.00
- Market cap
- ₹2,216 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 51.7×Sector 46.5×
- Promoter holding
- 51.70%-0.82% QoQ
- FII holding
- 12.34%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Earnings Call Transcript: Key Takeaways
Sakar Healthcare delivered exceptional growth as its oncology segment scales, with EBITDA doubling and margins expanding significantly due to product-mix shifts. Management is pivoting from a non-oncology focus to high-margin oncology formulations and APIs.
- Call
- Guides 35% growth
Sakar Healthcare Results Update
Sakar Healthcare reported Q2 FY27 revenue of ₹87.42 Cr and PAT of ₹11.31 Cr, up 149% YoY. EBITDA rose 114% to ₹24.35 Cr on strong oncology approvals and commercial supply commencement.
Sakar Healthcare Q2 FY27 Results: Net Profit ₹11.3 Cr, Up 151.1% YoY
Sakar Healthcare Ltd reported revenue from operations of ₹87.4 Cr (+51.7% YoY) and net profit of ₹11.3 Cr (+151.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹11.3 Cr · +151.1% YoY
Sakar Healthcare Board Meeting Date
Sakar Healthcare has scheduled a board meeting for October 23, 2026, to approve its unaudited quarterly financial results for the period ended September 2026.
Sakar Healthcare Business Update
Sakar Healthcare says its oncology export model is expanding, with 22 Marketing Authorizations granted and commercial supply starting from its EU GMP site. No monetary value stated.
Sakar Healthcare Other Announcement
Sakar Healthcare Limited appointed M/s. Kashyap R. Mehta & Partners as the company's Secretarial Auditors for a five-year term, effective September 22, 2026, following shareholder approval at the AGM.